Weight · Rx required

The Heavy Hitter Stack

Dual-action weight support.

Tier 1 · FDA-approved / strong evidence

The story

Dual-action weight support. Tirzepatide works on two appetite hormones at once and has produced some of the largest weight-loss numbers ever recorded for a medication. Same supportive B12 and supplies as the Kickstart.

Why this combination

Tirzepatide hits both GLP-1 and GIP pathways, which in trials added up to more appetite control than GLP-1 alone. B12 steadies energy while intake drops.

What to expect

In SURMOUNT-1, average weight loss reached ~15–22.5% by dose over 72 weeks, with ~9 in 10 losing at least 5% at the top dose. Longer-term data showed sustained loss and reduced progression from prediabetes to diabetes. Dose climbs gradually.

Risks & considerations

Same gastrointestinal profile and rodent thyroid-tumor boxed warning and contraindications as semaglutide. Rare pancreatitis/gallbladder issues. Greater blood-sugar lowering if combined with other glucose-lowering medicines. Muscle loss and post-stop regain apply.

Sources

  1. SURMOUNT-1, NEJM 2022
  2. SURMOUNT-1 3-year extension, NEJM 2024

What's in the stack

  • Tirzepatide + B12 injection
  • Injection supplies